The strong Q2 beat and raised guidance, combined with the favorable Guardant litigation outcome and first-ever AstraZeneca CDx deal, represent a significant inflection point. Monitor the Q3 earnings call for progress on the AstraZeneca CDx revenue ramp and the MSK joint venture. The company expects to approach adjusted EBITDA breakeven by end of 2026 and cross to positive in H2 2027 — any deviation from this trajectory would be a key risk.
Price Chart
Executive Summary
SOPHiA GENETICS reported Q2 2026 results with revenue of $23.3M (+27% YoY), beating the raised guidance range. The company raised full-year 2026 revenue guidance to $94M-$96M (from $92M-$94M) and signed two companion diagnostic programs with AstraZeneca. Net loss was flat YoY at $22.4M, while adjusted EBITDA loss improved 27% to -$8.8M. The balance sheet was strengthened with a $57.5M public offering, bringing cash to $107.7M. The Guardant Health litigation was resolved favorably at the UPC Court of Appeal, removing provisional injunction risk in the EU.
Key Facts
- Revenue of $23.3M in Q2 2026, up 27% YoY from $18.3M
- Raised FY2026 revenue guidance to $94M-$96M (22-24% YoY growth) from prior $92M-$94M
- Signed two companion diagnostic (CDx) programs with AstraZeneca, the first in company history
- Adjusted EBITDA loss improved 27% YoY to -$8.8M from -$12.0M
- Cash and cash equivalents of $107.7M, up from $70.3M at year-end 2025, after $57.5M public offering
- Net dollar retention (NDR) increased to 117% from 107% YoY
- U.S. revenue grew 64% YoY; U.S. analysis volume grew 60% YoY
- Liquid biopsy revenue grew 80% YoY; 80 customers signed across 30+ countries
- UPC Court of Appeal rejected Guardant's appeal, confirming no provisional injunction on MSK-ACCESS
- Platform analysis volume of 115,432, up 22% YoY; 542 core genomics customers vs 490 a year ago
Financial Impact
Revenue growth of $4.99M (+27%) YoY in Q2; raised FY guidance by $2M at midpoint; adjusted EBITDA loss narrowed by $3.2M YoY in Q2
Risk Factors
- Guardant Health litigation in the UK remains pending and could still result in injunctive relief or damages
- The company remains unprofitable with a net loss of $22.4M in Q2; path to profitability depends on continued revenue growth and cost discipline
- Potential changes to SEC Foreign Private Issuer (FPI) definition could impose additional compliance costs or require listing on a non-US exchange
- High customer concentration risk — largest customer represents 16% of accounts receivable
- Substantial debt of $48M with high interest costs (SOFR + 6.25%) and $50.2M in cloud hosting commitments through 2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-052125 |
| Document: sophiageneticssaex992q22026.htm | 0001628280-26-052125 |
| Document: sophiageneticssaex993q22026.htm | 0001628280-26-052125 |
| Document: soph-20260630.htm | 0001628280-26-052125 |
| Document: 0001628280-26-052125-index-headers.html | 0001628280-26-052125 |
| Document: 0001628280-26-052125-index.html | 0001628280-26-052125 |
| Document: 0001628280-26-052125.txt | 0001628280-26-052125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | Insider Cluster | $7.29 $7.05 | ▼ −3.29% | ▼ −2.28% | $7.52 (+3.16%) |
Oct 5, 2026 21d ago | 144 | $7.38 $7.09 | ▼ −3.93% | ▼ −3.79% | $7.52 (+1.90%) |
Sep 16, 2026 5w ago | Insider Cluster | $8.53 $8.26 | ▼ −3.17% | ▼ −4.02% | $7.52 (−11.84%) |
Sep 14, 2026 6w ago | Insider Cluster | $7.96 $8.07 | ▲ +1.38% | ▼ −0.73% | $7.52 (−5.53%) |
Aug 31, 2026 8w ago | Insider Cluster | $8.43 $7.68 | ▼ −8.84% | ▼ −8.92% | $7.52 (−10.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $8.92 $8.30 | ▼ −6.95% | ▼ −7.22% | $7.52 (−15.70%) |
Aug 25, 2026 8w ago | 144 | $8.53 $8.28 | ▲ +2.93% | ▲ +2.81% | $7.52 (+11.84%) |
Aug 21, 2026 9w ago | Insider Cluster | $8.45 $8.40 | ▼ −0.59% | ▼ −1.06% | $7.52 (−11.01%) |
Aug 21, 2026 9w ago | Insider Cluster | $8.45 $8.40 | ▼ −0.59% | ▼ −1.06% | $7.52 (−11.01%) |
Aug 14, 2026 10w ago | Insider Cluster | $7.63 $8.45 | ▼ −10.75% | ▼ −11.94% | $7.52 (+1.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers